Flat-dose nivolumab well-tolerated, active for advanced NSCLC in Asians
14 Jul 2020
byChristina Lau
Flat-dose nivolumab, administered as a 30-minute infusion, is well tolerated and active in Asian patients with previously treated advanced non-small-cell lung cancer (NSCLC), according to results of the phase IIIb CheckMate 870 study.
Flat-dose nivolumab well-tolerated, active for advanced NSCLC in Asians
14 Jul 2020